- Home
- FLUX vs IGC Comparison
FLUX vs IGC Comparison
Compare FLUX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- IGC
- Stock Information
- Founded
- FLUX N/A
- IGC 2005
- Country
- FLUX United States
- IGC United States
- Employees
- FLUX N/A
- IGC N/A
- Industry
- FLUX Industrial Machinery/Components
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- IGC Health Care
- Exchange
- FLUX Nasdaq
- IGC Nasdaq
- Market Cap
- FLUX 20.2M
- IGC 20.2M
- IPO Year
- FLUX N/A
- IGC N/A
- Fundamental
- Price
- FLUX $1.83
- IGC $0.29
- Analyst Decision
- FLUX Strong Buy
- IGC Strong Buy
- Analyst Count
- FLUX 3
- IGC 2
- Target Price
- FLUX $6.33
- IGC $3.88
- AVG Volume (30 Days)
- FLUX 38.2K
- IGC 196.9K
- Earning Date
- FLUX 05-08-2025
- IGC 06-23-2025
- Dividend Yield
- FLUX N/A
- IGC N/A
- EPS Growth
- FLUX N/A
- IGC N/A
- EPS
- FLUX N/A
- IGC N/A
- Revenue
- FLUX $63,074,000.00
- IGC $1,236,000.00
- Revenue This Year
- FLUX $11.85
- IGC N/A
- Revenue Next Year
- FLUX $13.10
- IGC $16.45
- P/E Ratio
- FLUX N/A
- IGC N/A
- Revenue Growth
- FLUX N/A
- IGC 1.65
- 52 Week Low
- FLUX $1.15
- IGC $0.25
- 52 Week High
- FLUX $4.98
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- FLUX 54.30
- IGC 46.51
- Support Level
- FLUX $1.77
- IGC $0.28
- Resistance Level
- FLUX $2.13
- IGC $0.32
- Average True Range (ATR)
- FLUX 0.17
- IGC 0.01
- MACD
- FLUX 0.02
- IGC -0.00
- Stochastic Oscillator
- FLUX 45.45
- IGC 26.50
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.